A Pilot Study of the Immunological Effects of Neo-Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Description: 

INCB024360 is an IDO1 inhibitor with the capacity to normalize serum kynurenine/tryptophan (Kyn/Trp) ratios. The goal of the trial is to determine the extent to which a regimen of INCB024360 that normalizes serum Kyn/Trp ratios alters the tumor microenvironment, including the number and character of tumor infiltrating lymphocyte and the gene signature in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

Study Number: 

I 248013

Phase: 
I
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02042430

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.